GlassScriptPhysician profile
Nathaniel Allen Steele
NPI 1417433772
$2,643.75
in general payments reported to CMS, 2019-2025
32 companies · $54.69 in 2025
The $54.69 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,390 · 2022: $1,060 · 2023: $50.85 · 2024: $87.93 · 2025: $54.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.26 | 2021-2022 | |
| Abbvie INC. | $302.83 | 2021-2022 | |
| Amgen INC. | $301.59 | 2021-2022 | |
| Dexcom, INC. | $144.28 | 2021-2022 | |
| Amarin Pharma, INC. | $143.58 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $123.48 | 2021-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Horizon Therapeutics Plc | $105.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.85 | 2021-2022 | |
| Lilly USA, LLC | $93.07 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $76.67 | 2021-2024 | Flumist Quadrivalent |
| Biohaven Pharmaceutical Holding Company LTD. | $75.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.08 | 2021-2022 | |
| Astellas Pharma US INC | $68.06 | 2021 | |
| Sanofi Pasteur INC. | $59.23 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.21 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $41.00 | 2021-2022 | |
| Genentech USA, INC. | $41.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.17 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $36.25 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $35.49 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.45 | 2022-2024 | Bexsero |
| Ironwood Pharmaceuticals, INC | $34.78 | 2021 | |
| Eisai INC. | $32.98 | 2022 | |
| Mylan Specialty L.P. | $31.23 | 2021 | |
| Redhill Biopharma INC. | $30.32 | 2021-2022 | |
| Seqirus USA INC | $23.42 | 2024 | Flucelvax |
| Pfizer INC. | $19.49 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $15.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.86 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.93 | 2025 | Kristalose |
| Biogen, INC. | $12.82 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.